Raber, J., Huang, Y., Ashford, J.W. (2004). ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641-650. (

Caselli, R.J., Dueck, A. C., Osborne, D., Sabbagh, M.N., Connor, D.J., Ahern, G.L., Baxter, L.C., Rapcsack, S.Z., Shi, J., Woodruff, B.K., et al. (2009). Longitudinal modeling of age-related memory decline and the ApoE Ɛ4 effect. N. Engl. J. Med. 361, 255-263. (

Verghese, P.B., Castellano, J.M., and Holtzman, D.M. (2011). Roles of apolipoprotein E in Alzheimer's Disease and other neurological disorders. Lancet Neurol. 10, 241–252. (

Liu, C.C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol. 9, 106–118. (

Mahley, R.W., Huang, Y. (2012). Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 76, 871-885. (